Selecting disease modifying drugs for neurodegenerative diseases remains a challenge and participates in the high failure rate for drug development in these indications. Mitoselect® is a line of HCA, industry validated, phenotypic models for selection of drug candidates intended to slow or reverse neurodegeneration using PATIENT-DERIVED cell.
These models have proven usefull for the selection of drug candidates currently in Phase I-III clinical trial in diverse indications. Mitoselect® Models are available for Huntington’s disease, Alzheimer’s disease (sporadic), Parkinson’s disease (sporadic) and Parkinson’s disease (LRRK2 mutation).
Why use Mitoselect® models?
Identify drugs with disease-modifying potential.
Use a well-characterized technology based on mitochondrial behavior assessment.
Results are well translated to the clinic, better than using any animal model.
Assess drug response heterogeneity using a larger number of donors.
A whole R&D team of mitochondrial experts at your service.
Why is Mitoselect® the best tool to target Neurodegenerative diseases ?
Mitoselect® uses the proprietary technology Mitostream® to phenotypically quantify and qualify patient derived somatic cells or iPSCs derived cells.
These outcomes can easily be transposed into a response-signature to your drug
A customized design to answer your specific need.
CONTACT US FOR A DEMONSTRATION OF MITOSELECT POWER THROUGH THE PAST EXPERIENCE OF OUR CLIENTS